Key result
Pioglitazone attenuates LV hypertrophy and fibrosis while improving diastolic function in hypertensive rats.
Why the study?
Cardiac hypertrophy is common in diabetes and an independent risk factor for cardiac morbidity and mortality, but the effects of pioglitazone on cardiac hypertrophy and signaling in salt-sensitive hypertension were unclear.
Does pioglitazone attenuate cardiac hypertrophy and improve diastolic function in salt-sensitive hypertensive rats?
Population
Dahl salt-sensitive hypertensive rats fed a high-salt diet from 7 weeks of age
Comparison
Pioglitazone (2.5 mg/kg per day) vs vehicle
Design
Preclinical experimental study
Authors
Loading...
May attenuate LVH in hypertensive rat models; leaves open translation to diabetic cardiomyopathy in humans.
Does pioglitazone attenuate cardiac hypertrophy and improve diastolic function in salt-sensitive hypertensive rats?
Pioglitazone attenuates left ventricular hypertrophy and fibrosis in salt-sensitive hypertensive rats, likely through AMPK activation and Akt inhibition.
Kato et al. (2008) studied Cardiac hypertrophy in salt-sensitive hypertension. Pioglitazone vs. Vehicle was evaluated on Cardiac hypertrophy, fibrosis, diastolic dysfunction, and signaling pathways. Pioglitazone treatment ameliorated left ventricular hypertrophy and fibrosis, improved diastolic function, and increased serum adiponectin and AMPK phosphorylation in salt-sensitive hypertensive rats.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: